| Recognized Soohyun Lew's Extensive Experience and Expertise in the Pharmaceutical and Medical Device Industries
| Participation in the Development and Revision of International Pharmaceutical Regulatory Guidelines
| JNPMEDI Plans to Provide Innovative and Advanced Services by Adhering to International Pharmaceutical Standards
Soohyun Lew, Vice President of JNPMEDI, a medical data platform company led by CEO Kwunho Jeong, has been appointed as an expert committee member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
The IFPMA is a non-governmental, non-profit organization established in 1968 to enhance human health and welfare and strengthen the ethical standards of the pharmaceutical industry. The organization is a standing observer of the International Council for Harmonisation (ICH), an international body that leads the harmonization of standards for the quality, safety, and efficacy of medicines. As an IFPMA expert committee member, Soohyun Lew will participate in ICH assemblies and committees.
Soohyun Lew’s selection acknowledges his extensive experience and expertise in clinical trials and the pharmaceutical and medical device industries. Notably, he was recognized for his knowledge in developing and evaluating non-clinical trials for oligonucleotide-based therapies, which is a crucial requirement for expert committee members.
In his new role, Soohyun Lew will be involved in the overall process of developing and revising international pharmaceutical regulatory guidelines overseen by the ICH. He will serve as an IFPMA Task Force expert, providing professional feedback on agenda items and outcomes discussed in ICH working groups, particularly concerning the development of guidelines for non-clinical safety testing of oligonucleotide-based therapies. This involvement is expected to directly benefit domestic pharmaceutical companies developing new drugs.
CEO Kwunho Jeong stated, "Soohyun Lew's appointment as an IFPMA expert committee member acknowledges the expertise of our key personnel. JNPMEDI will continue to comply with international standards and provide innovative products and services accordingly."
Soohyun Lew has over 30 years of experience as a specialist in family medicine and clinical pharmacology at Yonsei University College of Medicine. He has served as CEO of Seoul CRO and DreamCIS, Medical Director at GE Healthcare and Novartis, and has been recognized for his expertise. Additionally, he has served as an advisor for global clinical trials at KoNECT and as a committee member for the ICH advisory board at the Ministry of Food and Drug Safety (MFDS), accumulating extensive experience and knowledge in clinical and medical fields through global regulatory harmonization, pharmaceutical regulatory development, networking expansion, and medical consulting.
| Recognized Soohyun Lew's Extensive Experience and Expertise in the Pharmaceutical and Medical Device Industries
| Participation in the Development and Revision of International Pharmaceutical Regulatory Guidelines
| JNPMEDI Plans to Provide Innovative and Advanced Services by Adhering to International Pharmaceutical Standards
Soohyun Lew, Vice President of JNPMEDI, a medical data platform company led by CEO Kwunho Jeong, has been appointed as an expert committee member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
The IFPMA is a non-governmental, non-profit organization established in 1968 to enhance human health and welfare and strengthen the ethical standards of the pharmaceutical industry. The organization is a standing observer of the International Council for Harmonisation (ICH), an international body that leads the harmonization of standards for the quality, safety, and efficacy of medicines. As an IFPMA expert committee member, Soohyun Lew will participate in ICH assemblies and committees.
Soohyun Lew’s selection acknowledges his extensive experience and expertise in clinical trials and the pharmaceutical and medical device industries. Notably, he was recognized for his knowledge in developing and evaluating non-clinical trials for oligonucleotide-based therapies, which is a crucial requirement for expert committee members.
In his new role, Soohyun Lew will be involved in the overall process of developing and revising international pharmaceutical regulatory guidelines overseen by the ICH. He will serve as an IFPMA Task Force expert, providing professional feedback on agenda items and outcomes discussed in ICH working groups, particularly concerning the development of guidelines for non-clinical safety testing of oligonucleotide-based therapies. This involvement is expected to directly benefit domestic pharmaceutical companies developing new drugs.
CEO Kwunho Jeong stated, "Soohyun Lew's appointment as an IFPMA expert committee member acknowledges the expertise of our key personnel. JNPMEDI will continue to comply with international standards and provide innovative products and services accordingly."
Soohyun Lew has over 30 years of experience as a specialist in family medicine and clinical pharmacology at Yonsei University College of Medicine. He has served as CEO of Seoul CRO and DreamCIS, Medical Director at GE Healthcare and Novartis, and has been recognized for his expertise. Additionally, he has served as an advisor for global clinical trials at KoNECT and as a committee member for the ICH advisory board at the Ministry of Food and Drug Safety (MFDS), accumulating extensive experience and knowledge in clinical and medical fields through global regulatory harmonization, pharmaceutical regulatory development, networking expansion, and medical consulting.